

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WUXI BIOLOGICS (CAYMAN) INC.**

**藥明生物技術有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2269)**

**CHANGE OF ADDRESS OF PRINCIPAL PLACE OF  
BUSINESS IN HONG KONG AND  
CHANGE OF ADDRESS OF HONG KONG BRANCH SHARE  
REGISTRAR AND TRANSFER OFFICE**

The board of directors (the “**Board**”) of WuXi Biologics (Cayman) Inc. (the “**Company**”) hereby announces that with effect from August 15, 2022, the address of the Company’s principal place of business in Hong Kong will be relocated from Level 54, Hopewell Centre, 183 Queen’s Road East, Hong Kong to:

**5/F, Manulife Place, 348 Kwun Tong Road, Kowloon, Hong Kong**

The Board also announces that with effect from August 15, 2022, the Hong Kong Branch Share Registrar and Transfer Office of the Company, Tricor Investor Services Limited (the “**Branch Share Registrar**”), will change its address from Level 54, Hopewell Centre, 183 Queen’s Road East, Hong Kong to:

**17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong**

All telephone and facsimile numbers of the Branch Share Registrar will remain unchanged.

For and on behalf of the Board  
**WuXi Biologics (Cayman) Inc.**  
**Dr. Ge Li**  
*Chairman*

Hong Kong, August 12, 2022

*As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Dr. Ning Zhao, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Kenneth Walton Hitchner III as independent non-executive Directors.*

\* *For identification purpose only*